Monopar Therapeutics (MNPR) director Christopher M. Starr exercised stock options for 8,400 common shares at $0.005 per share on October 1, 2026, and sold 8,400 shares in three transactions: 4,631 at a weighted average price of $78.09, 2,970 at $78.82, and 799 at $79.67. The respective sale prices ranged from $77.50 to $78.49, $78.50 to $79.49, and $79.50 to $80.01, inclusive. The transactions were effected pursuant to a Rule 10b5-1 Plan executed May 28, 2026. The reported positions following the transactions include 8,400 stock options and 9,880 common shares held by the Christopher M. Starr and Sheri L. Starr Revocable Trust, for which Starr serves as trustee.
Monopar Therapeutics (MNPR) Chief Operating Officer Andrew Cittadine had 4,384 restricted stock units vest and settle on September 30, 2026, resulting in 4,384 common shares. The issuer withheld 1,944 common shares to pay applicable withholding tax at $79.67 per share. His reported post-transaction restricted stock unit balance was 35,115 units.
Monopar Therapeutics Chief Executive Officer Chandler Robinson reported 9,801 restricted stock units surrendered for 9,801 common shares upon vesting and settlement on September 30, 2026. The issuer withheld 4,344 shares at $79.67 per share for withholding taxes. His reported post-transaction balance was 83,602 restricted stock units; the filing also lists 62,815 common shares held by the Chandler D. Robinson Irrevocable Trust. No Rule 10b5-1 plan is reported.
Monopar Therapeutics Chief Financial Officer Quan Anh Vu reported vesting and settlement of 614 restricted stock units on September 30, 2026, for 614 common shares. The issuer withheld 180 shares to pay applicable withholding tax at $79.67 per share. A total of 7,984 restricted stock units remained after the transaction; the original award was 9,826 restricted stock units granted December 2, 2025.
Monopar Therapeutics (MNPR) director Christopher Starr reported a proposed sale of 16,800 common shares, with an aggregate market value of $1,338,456. The notice lists October 1, 2026, as the approximate sale date and states that the shares were and will be received through stock-option exercises over the next three months. Morgan Stanley Smith Barney LLC is listed in connection with the sale.
Monopar Therapeutics Chief Executive Officer Chandler Robinson exercised options for 14,056 common shares at $30 per share and 15,000 at $14 per share on September 24, 2026. He also sold 10,450, 9,638, 8,368 and 600 shares at weighted average prices of $87.15, $87.96, $88.97 and $89.79 per share, respectively, on that date. The transactions were effected under a Rule 10b5-1 Plan executed June 25, 2026. The report also lists 62,815 shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
Monopar Therapeutics Inc. is named as issuer for Chandler Robinson’s proposed sale of 29,056 common shares, with an aggregate market value of $2,597,025.28. The approximate sale date is September 24, 2026; Morgan Stanley Smith Barney LLC is listed as broker and NASDAQ as the exchange. Acquisition details identify an exercise of stock options from the issuer and list cash.
Monopar Therapeutics (MNPR) director Kim R. Tsuchimoto reported an amended set of transactions on August 26, 2026, correcting a prior Form 4. The director exercised stock options for 2,055 shares at an exercise price of $30.00 and 2,035 shares at $14.00, receiving an equal number of common shares. On the same date, a total of 4,090 common shares were sold in multiple trades at weighted average prices between $108.83 and $113.84 per share, with underlying trade ranges from $108.07 to $114.34. All option exercises and sales were effected pursuant to a Rule 10b5-1 Plan executed on May 27, 2026. Following these transactions, 11,486 shares are reported as held indirectly by the Kim R. Tsuchimoto Trust dated October 6, 2015.
Monopar Therapeutics (MNPR) director Raymond Anderson amended a prior insider report to include previously omitted option exercises and to reflect Monopar’s 5-for-1 reverse stock split effective August 12, 2024. On August 25, 2026, he exercised options for 3,142 shares of common stock at a $30.00 exercise price and sold 3,142 shares in three open-market transactions at weighted average prices of $110.04, $111.07, and $113.05. All transactions were effected under a Rule 10b5-1 trading plan executed on May 26, 2026.
Monopar Therapeutics (MNPR) reported that Acting Chief Medical Officer Patrice Rioux exercised 1,380 Stock Options for Common Stock on 2026-08-26 at an exercise price of $0.005 per share, converting them into 1,380 Common Shares. On the same date, 1 Common Share was sold at $111.26 per share. The option exercise exhausted this particular option grant, leaving 0 derivative shares reported as remaining from it. These transactions were effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.